Skip to main content
Log in

Statin Therapy and Plasma C-Reactive Protein Levels in Primary Prevention

  • Letter to the Editor
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the predictions of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.

    PubMed  Google Scholar 

  2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and risks of cardiovascular events in apparently healthy men. N Engl J Med 1997;336:973-979.

    PubMed  Google Scholar 

  3. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. For the Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-235.

    PubMed  Google Scholar 

  4. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1329-1445.

    Google Scholar 

  5. Kothe H, Dalhoff K, Rupp J, et al. Hydroxymethylglutarylcoenzmye a reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 2000 101:1760-1763

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dzien, A., Dzien-Bischinger, C., Hoppichler, F. et al. Statin Therapy and Plasma C-Reactive Protein Levels in Primary Prevention. Cardiovasc Drugs Ther 14, 699–700 (2000). https://doi.org/10.1023/A:1007887503287

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007887503287

Navigation